When Akamai announced its LayerX acquisition, the company joined a growing list of vendors adding secure enterprise browsers to their product portfolios.
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after …
Tender offer for Recordati; Sobi’s gout drug passes Phase 3 test
Plus, news about Immunovant and Retro Biosciences. 💸 CVC and GBL launch tender offer for Recordati: CVC Capital Partners and Groupe Bruxelles Lambert (GBL), a Belgian investment holding company, launched their cash voluntary tender
Verizon DBIR: Healthcare Fends Off Increased Social Engineering Attacks
Ransomware and vendor breaches persist, but the 2026 Data Breach Investigations Report (DBIR) highlights how evolving social engineering tactics make the sector more vulnerable.
Why one health AI unicorn is giving away its service for free
As health tech gets more competitive, a strategy companies use to stand out is providing their products for free. They’re betting this will help build up a large and loyal …
Novartis says Avidity’s science could apply beyond muscular dystrophies
Novartis said it’s working to get the most out of its $12 billion acquisition of Avidity Biosciences by finding ways to apply its underlying science to diseases beyond muscular dystrophy. The drugmaker’s 2025
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s …
Ibrance heirs, Gilead’s Tubulis data and more at #ASCO26
All of the regular ASCO abstracts dropped Thursday afternoon, with the biggest news coming from the VEGF bispecific race, Merck and Kelun-Biotech’s TROP2 ADC known as sac-TMT, and multiple …
Amgen CFO to follow David Reese into retirement; Josh Smiley is out at Zai Lab
→ Peter Griffith will be the second high-profile exec to leave Amgen this year when he retires on Sept. 1. Thomas Dittrich will replace him as CFO and return to Amgen …
GBL joins CVC in €10.7bn takeover bid for Recordati
A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Google I/O showed how the path for AI-driven science is shifting
During Tuesday’s Google I/O keynote, Demis Hassabis, the CEO of Google DeepMind, proclaimed that we are currently “standing in the foothills of the singularity.” It was a striking statement—the singularity is the theoretical future moment when AI rapidly exceeds human intelligence and dramatically transforms the world. But what struck me as I listened in the […]
AbbVie, GSK race up patient reputation leaderboard in the UK
AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards.